Pathological cell death occurs in the course of Huntington'sdisease (HD), Parkinson's disease,Alzheimer's disease, and amyotrophic lateral sclerosis (ALS) and also after acute brain trauma and cerebralischemia. Drugs that inhibit caspases (enzymes that drive programmed cell death) slow down chronicdegenerations and decrease damage following acute insult. Because the release of cytochrome c frommitochondria triggers caspase activation, blocking that critical step should derail the cell death program. Ourproposed scheme for drug discovery has five portions which constitute the following five Specific Aims: 1) Testing compounds that inhibit the release cytochrome c for their ability to protect cultured neurons from pro-apoptotic stimuli in four cellular models of neurological disease. 2) Assaying molecular changes (i.e., caspase activation, post-translational changes to Bcl-2 proteins, release from mitochondria of apoptogenic factors, loss of mitochondrial membrane potentials) in these cultured cells. Each compound found to be protective in (1) will be tested for its effects on these biochemical and physiological processes. 3) Testing in an animal model of HD (the R6/2 mouse) those experimental drugs that rescue cultured neurons from cell death. 4) Determining the molecular and physiological changes in the brains of R6/2 mice that result from administration of these drugs. 5) Testing in R6/2 mice whether the beneficial effects of novel drugs add to those of known therapies for HD. The Preliminary Results section shows that minocycline has parallel effects upon isolatedmitochondria, cultured neurons, and tissues of the mouse CNS. Such observations motivated a screen of 1040compounds in an NINDS library for their ability to block cytochrome c release from purified mitochondria.The underlyingassumption is that should other drugs have action similar to minocycline in the cell-freesystem, they are apt to have comparable neuroprotective effects in vivo. The results of this screen arepresented. Additional data on minocycline follows, i.e., that the drug rescues neurons in cellular models ofcell death and slows neurological degeneration in R6/2 mice. Using the program outlined above, we hope toidentify and characterize other compounds that slow the progress of HD.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-NDBG (09))
Program Officer
Sutherland, Margaret L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Zhang, Yi; Cook, Anna; Kim, Jinho et al. (2013) Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 55:26-35
Zhang, Yi; Wang, Xin; Baranov, Sergei V et al. (2011) Dipyrone inhibits neuronal cell death and diminishes hypoxic/ischemic brain injury. Neurosurgery 69:942-56
Wang, Xin; Sirianni, Ana; Pei, Zhijuan et al. (2011) The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci 31:14496-507
Yanamadala, Vijay; Friedlander, Robert M (2010) Complement in neuroprotection and neurodegeneration. Trends Mol Med 16:69-76
Zhang, Yu; Engelman, Joshua; Friedlander, Robert M (2009) Allele-specific silencing of mutant Huntington's disease gene. J Neurochem 108:82-90
Wang, Xin; Zhu, Shan; Pei, Zhijuan et al. (2008) Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J Neurosci 28:9473-85